Navigation Links
Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Date:8/27/2007

-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to

Upstream-

-Initial Compounds Demonstrate Promising In Vitro Activity Against Devastating Parasitic Diseases Affecting 300 Million People Worldwide-

VANCOUVER, B.C., Aug. 27 /PRNewswire-FirstCall/ -- Upstream Biosciences Inc. (OTC Bulletin Board: UPBS) today announced it has completed the acquisition of Pacific Pharma Technologies Inc., an early stage biopharmaceutical company with a proprietary technology platform that combines artificial intelligence, advanced computational methods and chemical diversity techniques to discover new drugs. This technology has already generated novel compounds that in laboratory studies demonstrate both human and veterinary potential against major tropical parasitic diseases.

"This acquisition significantly broadens our strategic focus and provides Upstream with important new capabilities," said Joel L. Bellenson, Chief Executive Officer of Upstream. "We believe the innovative technology platform pioneered by Pacific Pharma may have substantial commercial potential in a number of therapeutic areas and it fits well with our existing core competencies in computational-based approaches to biomarker identification. Pacific Pharma has also generated novel compounds that have exhibited activity against targets relevant to cancer, the focus of our biomarker programs."

In screening studies in vitro, Pacific Pharma's lead compounds have demonstrated encouraging signs of efficacy against leishmaniasis and African sleeping sickness (trypanosomiasis). These parasites, which belong to a family of protozoa species that include Chagas disease and malaria, infect millions of individuals in Africa, South Asia and South America. Current treatments are often toxic, ineffective, inconvenient and expensive. In addition, recent reports document
'/>"/>

SOURCE Upstream Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
(Date:5/4/2015)... 4, 2015  Clinical Support Services, Inc. (CSS) ... completed preliminary analysis of Pharmacologic Adverse Events in ... Clinical Support Services, Inc. clinical staff were used ... currently taking psychiatric medications to assess the frequency ... 93% of patients experienced at least one ADE ...
(Date:5/4/2015)... PLEASANTON, Calif. , May 4, 2015 ... its coming out to this year,s PEGS conference and ... protein stability system for biologics. PEGS: The Essential Protein ... , May 4-8, 2015. The UNit lets ... than any other tool out there. Its 7 applications, ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3Unchained Labs Lets the UNit Loose 2
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:5/4/2015)... In a continuing effort to remain ... Per Wickstrom, the founder of Choices Recovery in South ... “Salute to the Oscars” celebration held on February ... floor of the luxurious Beverly Hilton Hotel. , ... sustainable product placement in TV and film, this daylong ...
(Date:5/4/2015)... York (PRWEB) May 04, 2015 Takeda ... $2.4 billion to settle thousands of Actos lawsuits ( ... medication increases the risk that a patient will develop ... April 28th, if 95% of those eligible for the ... nearly 9,000 bladder cancer cases currently pending in courts ...
(Date:5/4/2015)... SAN DIEGO, California (PRWEB) May 04, 2015 ... health plans to manage their health is critical to ... patient satisfaction and reducing costs, but this will require ... spectrum. This change also demands that health systems move ... to speakers who took part in the third live ...
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
(Date:5/4/2015)... 04, 2015 The opportunity for children to ... are the motivating forces behind The Fairy Godmother Next Door, ... author Amy L. Stark. , The inspiration for the enchanting ... door comes from Stark’s desire to be a fairy godmother. ... fairy godmother to my neighbors’ children since they were born. ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... Initiative (WHI) report show that hormone therapy is associated with ... well as an increased risk of developing invasive breast cancer ... and preventive medicine at the University at Buffalo and one ... JAMA , says the breast cancers found in these ...
... a little-known variety of the grain that is the ... help soothe the inflammation involved in allergies, asthma, and other ... Agricultural and Food Chemistry . Mendel Friedman and colleagues ... benefits of eating black rice bran. Bran is the outer ...
... HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay News) ... (CML) who decided to stop taking the cancer drug Gleevec ... The study, published online Oct. 19 in The ... that the drug might go beyond long-term cancer control and ...
... Jordan, 20 October 2010 Elsevier Middle East announces ... ( JIPH ) has been selected for inclusion in MEDLINE, ... Medicine (NLM). Citations for articles indexed, the indexing terms and ... PubMed ( www.pubmed.gov ). Indexing using the US National Library ...
... HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay News) -- Not only ... breast cancer, new research finds, but it also ups the risk ... chances of dying. A study appearing in the Oct. 20 ... is at odds with previous observational studies that had suggested a ...
... TUESDAY, Oct. 19 (HealthDay News) -- Heavy alcohol and marijuana ... persist into adulthood, according to a new study. The ... scored lower than their abstinent peers on tests measuring a ... professor of psychiatry at the University of New Mexico School ...
Cached Medicine News:Health News:Hormone therapy increases invasive breast cancer and mortality, WHI 11-year follow up finds 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 3Health News:Study Shows HRT Even Riskier Than Thought 2Health News:Study Shows HRT Even Riskier Than Thought 3Health News:Binge Drinking, Pot Could Put Teens' Intellect at Risk: Study 2Health News:Binge Drinking, Pot Could Put Teens' Intellect at Risk: Study 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: